Examiner Cite

No

Initial*

Patent Number

Kind

publisher, city and/or country where published.

Code1

Issue Date

Remove

Remove

Τ۶

Figures Appear

Pages, Columns, Lines where

Relevant Passages or Relevant

	Application Number		10076632		
	Filing Date		2002-02-19		
NFORMATION DISCLOSURE	First Named Inventor	Paul Habermann			
STATEMENT BY APPLICANT Not for submission under 37 CFR 1.99)	Art Unit		1656		
NOTION SUBMISSION UNION ST OF K 1.339	Examiner Name	David J. Steadman			
	Attorney Docket Number		26482 (DEAV2001-0008)		

U.S. PATENTS

Name of Patentee or Applicant

of cited Document

	1									
If you wis	h to ad	d additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.		Add	_
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
		es,Columns,Lines where vant Passages or Relev res Appear								
	1									
If you wisl	If you wish to add additional U.S. Published Application citation information please click the Add button. Add									
	FOREIGN PATENT DOCUMENTS Remove									
		Country Code ²			Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS	
	1									
If you wis	If you wish to add additional Foreign Patent Document citation information please click the Add button Add									

NON-PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item

(book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s),

Evaminer Cite

Initials* No

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

pplication Number		10076632	
iling Date		2002-02-19	
irst Named Inventor	Paul I	Paul Habermann	
rt Unit		1656	
xaminer Name	David	rid J. Steadman	
ttorney Docket Number		26482 (DEAV2001-0008)	

	1	ROMANOS, M.A. et al., "Foreign Gene Expression in Yeast: a Review" Yeast (1992) pp. 423-488, Vol. 8				
	2	BIEHIMANS, R. et at, "The Large Surface Protein of Hepatitis B Virus is Retained in the Yeast Endoplasmic Reticulum and Provokes its Unique Enlargement" DNA and Cell Biology (1991) pp. 191-200, Vol. 10, no. 3				
	3	AGAPHONOV, M.O. et al., "Aggregation and Retention of Human Urokinase Type Plasminogen Activator in the Yeast Endoplasmic Retioulum" BMC Molecular Biology (2002) pp. 1-8, Vol. 3				
	4	SUH, J.K. et al., "Yeast Flavin-Containing Monocoxygenase is Induced by the Unfolded Protein Response" PNAS (4 January 2000) pp. 121-126, Vol. 97, no. 1				
	5	KIM, M.D. et al., "Coexpression of BiP Increased Antithrombotic Hirudin Production in Recombinant Saccharomyces Cerevisiee" Journal of Biotechnology (2003) pp. 81-87, Vol. 101				
	6	KJELDSEN, T., "Yeast Secretory Expression of Insulin Precursors" Applied Microbiol Biotechnol (2000) pp. 277-286, Vol. 54				
	7	KUELDSEN, T. et al., "Engineering-Enhanced Protein Secretory Expression in Yeast with Application to Insulin' The Journal of Biological Chemistry (2002) pp. 18245-18248, Vol. 277, no. 21				
If you wish to add additional non-patent literature document citation information please click the Add button Add						

E

EXAMINER SIgnature | Date Considered |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered, include copy of this form with next communication to applicant.

See Kind Code of USPTO Peterd Documents at sever USPTO CROY or MPEP 90.04. Estine dote that issued the document, by the two left of WIPO Standard ST3.) For Explanese patient for counters, the andication of the year of the region or the Empirical represent the serial results replied to the peter document.

*Kind of Counters by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible, *Applicant is to place a check mark here if Empirish languages translation is altituded.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10076632	
Filing Date		2002-02-19	
First Named Inventor	Paul Habermann		
Art Unit		1656	
Examiner Name	David J. Steadman		
Attorney Docket Number		26482 (DEAV2001-0008)	

CERTIFICATION STATEMENT

Please see 37	7 CFR 1.97	and 1.98 to	make the appro	priate selection(s	3):
---------------	------------	-------------	----------------	--------------------	-----

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(eV).

- See attached certification statement.
- The fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- A certification statement is not submitted herewith

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Xiaochun Zhu/	Date (YYYY-MM-DD)	2011-10-24
Name/Print	Xianchun Zhu	Registration Number	56311

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the stackhold from reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. (2)(2)(2) familishing of the information solicided is columbra; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmitine your submission related to a patient agricultant or patient. If you do not furnish the requested requirement of the patient of the pati

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a
 request involving an individual, to whom the record pertains, when the individual has requested assistance from the
 Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552a(m.).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuence of a plentin pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the inflations of 37 GPR 1.14, as a routine use, to the public if the record vas filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, one an opulie inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.